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P OSTOPERATIVE urinary retention is common with a reported incidence of 5 to 70%.1 It is linked 
to several factors including type of surgery, preexisting neu-
rologic disease, increased age, increased intravenous fluid 
administration, postoperative pain, and use of opioids and 
neuraxial anesthesia.1 The treatment of choice is bladder 
catheterization, which is associated with relevant morbidity 
(patient discomfort, urethral trauma, urethral stricture, and 
urinary tract infections). The risk of urinary tract infection 
with a single catheterization is 1 to 2% and can rise by 5 to 
10% for every additional day with an indwelling catheter.2 
It is the most common nosocomial infection in the United 
States, accounting for more than 1 million cases each year 
and 900,000 additional hospital days/yr. Urinary tract infec-
tions are directly responsible for 13% of deaths related to 
nosocomial infections3 and are associated with high financial 
implications.4
Thoracic epidural analgesia (TEA) has been shown to pro-
vide the most effective analgesia as well as to facilitate post-
operative rehabilitation after major thoracic or abdominal 
surgery.5 TEA with bupivacaine alone or in combination 
with fentanyl or with fentanyl and epinephrine significantly 
inhibits detrusor function, which in turn results in clini-
cally relevant postvoid residual urine volume (PVR), which 
requires monitoring or catheterization.6–8 Ropivacaine, on 
the other hand, administered in the lumbar epidural space 
during labor, affects motor blockade of the lower extremi-
ties to a clinically relevant lesser degree than bupivacaine. 
Thus, the two local anesthetics may have different effects on 
What We Already Know about This Topic
• Epidural analgesia can provoke bladder dysfunction
• Whether there is less urinary retention with ropivacaine than 
bupivacaine remains unknown
What This Article Tells Us That Is New
• Postvoid bladder volume was less with ropivacaine than 
bupivacaine, and urine flow was better maintained
• Ropivacaine is preferable to bupivacaine for bladder function 
and may prevent catheterization in some patients
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ABSTRACT
Background: Thoracic epidural analgesia with bupivacaine resulted in clinically relevant postvoid residuals due to detrusor 
underactivity. This study aimed to compare the risk of bladder dysfunction with ropivacaine versus bupivacaine using postvoid 
residuals and maximum flow rates. Our hypothesis was that ropivacaine would result in lower postvoid residuals, because 
ropivacaine has been shown to have less effect on motor blockade.
Methods: In this single-center, parallel-group, randomized, double-blind superiority trial, 42 patients undergoing open renal 
surgery were equally allocated to receive epidural bupivacaine 0.125% or ropivacaine 0.2%, and 36 were finally included. 
Inclusion criterion was normal bladder function. Patients underwent urodynamic investigations preoperatively and during 
thoracic epidural analgesia. Primary outcome was the difference in postvoid residual preoperatively and during thoracic epi-
dural analgesia postoperatively. Secondary outcomes were changes in maximum flow rate between and within the groups.
Results: Median difference in postvoid residual (ml) from baseline to postoperatively was 300 (range, 30 to 510; P < 0.001) 
for bupivacaine and 125 (range, −30 to 350; P = 0.011) for ropivacaine, with a significant mean difference between groups 
(−175; 95% confidence interval −295 to −40; P = 0.012). Median difference in maximum flow rate (ml/s) was more pro-
nounced with bupivacaine (−12; range, −28 to 3; P < 0.001) than with ropivacaine (−4; range, −16 to 7; P = 0.025) with a 
significant mean difference between groups (7; 95% confidence interval 0 to 12; P = 0.028). Pain scores were similar. No 
adverse events occurred.
Conclusions: Postvoid residuals were significantly lower using ropivacaine compared to bupivacaine for thoracic epidural 
analgesia reflecting less impairment of detrusor function with ropivacaine. (Anesthesiology 2017; XXX:00-00)
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bladder function.9 However, the analgesic potency of ropiva-
caine is approximately 60% of that of bupivacaine.10
The objective of this study was to investigate the effect of 
ropivacaine in the thoracic epidural space on bladder func-
tion and compare it to the effect of equianalgesic doses of 
bupivacaine. The hypothesis being that ropivacaine would 
have less impact on bladder function, assessed by PVR and 
urodynamic investigations.
Materials and Methods
Ethics
This single-center, randomized, double-blind, parallel-group 
interventional superiority study was approved by the local 
ethics committee of the University Hospital of Bern (KEK 
Bern, Switzerland, KEKBE 390/14), prospectively registered 
at ClinicalTrials.gov (NCT02414373, principal investigator 
P. Y. Wuethrich, date of registration: March 26, 2015) and 
conducted in compliance with the Declaration of Helsinki 
and good clinical practice. Full trial protocol can be accessed 
on request. All patients gave preoperative written informed 
consent to participate.
Study Design and Patients
Patients planned for open renal surgery were screened for 
inclusion at the Department of Urology of the University 
Hospital of Bern, Bern, Switzerland. All recruited patients 
completed the validated International Prostate Symptom 
Score questionnaire.11 Only patients with no preexist-
ing lower urinary tract symptoms (Internationale Prostate 
Symptom Score less than or equal to 7) and a PVR less than 
100 ml (assessed by ultrasound) were included after provid-
ing written informed consent.12 Exclusion criteria were any 
contraindication to TEA and pregnancy (exclusion for sur-
gery per se).
Forty-two patients were equally randomly allocated to 
either TEA with bupivacaine 0.125% or ropivacaine 0.2% 
by a computer-generated randomization list without block-
ing, following the recommendation of the Consolidated 
Standards of Reporting Trials statements. The allocation 
sequence was prepared by an independent operator not 
involved in the study, and the allocation assignment was 
concealed in opaque sealed envelopes that were sequentially 
numbered. Patients were allocated to the treatment group by 
assigning them the sequentially numbered envelope with the 
lowest number. Patients and investigators of bladder func-
tion were blinded to the epidural solution administrated; the 
contents of the epidural mixture were not distinguishable 
because the vials were placed in a sealed opaque bag by an 
anesthesiologist not involved in the study before patient and 
investigator entered the urodynamic room.
Time Course and Intervention
After recruitment, the first (baseline) urodynamic investi-
gation was performed without TEA the day before surgery. 
Urodynamic investigations were performed according to 
good urodynamic practice.13 After placement of a 6 French 
transurethral dual channel catheter (B. Braun Medical, Ger-
many) and a 14 French rectal balloon catheter (Gaeltec, 
United Kingdom), the bladder was filled at a rate of 25 to 
50 ml/min with Ringer’s lactate solution at room tempera-
ture. The rectal catheter measures rectal, i.e., intraabdomi-
nal, pressure. Detrusor pressure is calculated by subtracting 
the intraabdominal pressure from the intravesical pressure 
resulting (e.g., during coughing) in the pressure increase 
produced by the detrusor muscle itself (detrusor pressure).13 
Parameters of both the storage phase (bladder volume at 
first desire to void, bladder volume at strong desire to void, 
maximum cystometric capacity (maximum filling volume), 
bladder compliance (relationship between change in bladder 
volume and change in detrusor pressure), and voiding phase 
(maximum detrusor pressure, detrusor pressure at maxi-
mum flow rate, maximum flow rate, and PVR were recorded 
(fig. 1). An Aquarius XT multichannel urodynamic system 
was used for all measurements (Laborie Medical Technolo-
gies Corp., Canada). The methods, definitions, and units 
accord with the standards recommended by the Interna-
tional Continence Society.14
All patients received a thoracic epidural catheter placed at 
the interspace T7–8 or T8–9 before induction of anesthesia. 
The insertion site was determined using the classic landmark 
method, whereby the spinal process of T7 was identified at 
the line intersecting the inferior tip of the scapulae in the sit-
ting position. An 18-gauge epidural needle was inserted by a 
paramedian or median approach, and the epidural space was 
identified with the loss-of-resistance technique. A test dose 
of 1.5 ml of lidocaine 20 mg/ml with 0.005 mg/ml epineph-
rine was given to rule out subarachnoidal or intravascular 
placement.
TEA was then activated 20 min before skin incision with 
bupivacaine 2.5 mg/ml at a rate of 6 to 10 ml/h in both 
groups during surgery. No opioids were administrated epi-
durally during surgery. General anesthesia was induced with 
propofol, fentanyl, and rocuronium and maintained with 
isoflurane. A transurethral catheter was inserted after induc-
tion and left in place until the next urodynamic investiga-
tion. At the end of surgery, continuous epidural analgesia 
was maintained with the epidural drug according to the ran-
domization: bupivacaine 1.25 mg/ml (bupivacaine group) 
(bupivacain 0.125% Bioren; Sintetica–Bioren, Switzerland) 
or ropivacaine 2 mg/ml (ropivacaine group; naropin 0.2% 
Sintetica; Sintetica–Bioren) using a CADD Legacy ambu-
latory infusion pump (model 6300; Deltec Inc., USA). 
The initial infusion rate was 8 ml/h, with additional bolus 
volumes of 5 ml (lockout time: 1 h). Higher concentrated 
ropivacaine was used to reach equipotent analgesia because 
analgesic potency of ropivacaine is approximately 60% of 
that of bupivacaine.10
The infusion rate was then adapted if necessary based 
on assessments made every 4 h to maintain a pain intensity 
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Fig. 1. (A) Example of a representative urodynamic tracing from a study patient showing one micturition at baseline. An electromy-
ography (EMG) shows tracing taken from the pelvic floor muscles by perianal surface electrodes. (B) A representative urodynamic 
tracing from a study patient showing one micturition cycle during thoracic epidural analgesia postoperatively with urinary reten-
tion due to detrusor muscle underactivity. Flow = voided urine measured on the scale over time; Pabd = intraabdominal pressure 
(measured by the rectal balloon); Pdet = detrusor pressure (calculated as difference from Pves – Pabd); PdetQmax = detrusor 
pressure at maximum flow rate; Pves = intravesical pressure; Qmax = maximum flow rate; Vinf = filling of the bladder.
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lower than 3 at rest and lower than 5 during mobilization on 
the numeric rating scale (NRS), in which 0 = no pain and 
10 = worst pain imaginable. The maximum infusion rate was 
15 ml/h. Additional rescue analgesia with a systemic administra-
tion of opioids (fentanyl) was permitted if the NRS was defined 
as a NRS of more than 5 after optimization of the TEA.
The level of sensory blockade was assessed by hyposensitivity 
to cold. A cold gel bag (Nexcare reusable cold pack; 3M, USA) 
with a surface of 4 cm2 was applied for 1 s to each dermatome.15
The second urodynamic investigation was performed on 
the second or third postoperative day around noon, depend-
ing on the patient’s mobilization. Patients were mobilized 
the evening after surgery (bedside mobilization) and then 
were encouraged to ambulate on postoperative day 1 (short 
walk on the ward). Segmental blockade was assessed at 8:00 
AM, and if necessary, the epidural mixture rate was optimized 
to achieve a segmental blockade above T6 and below T10, 
not exceeding T12 bilaterally. Potential risk factors for post-
operative urinary retention (postoperative rescue opioid 
requirement, postoperative nausea and vomiting, sedation) 
were also documented.
Endpoints
The primary endpoint was within-patient difference (Δ) in 
PVR (Δ = value during TEA postoperatively – baseline value) 
between the two groups. Secondary endpoints were within-
patient difference in bladder volume at first desire to void, 
bladder volume at strong desire to void, maximum cystomet-
ric capacity, bladder compliance, maximum detrusor pres-
sure, detrusor pressure at maximum flow rate, maximum flow 
rate, PVR between the time points (during TEA postopera-
tively vs. baseline), and postoperative pain scores according to 
the NRS. The bladder contractility index, which reflects the 
strength of the detrusor contraction, was calculated accord-
ing to the formula “detrusor pressure at maximum flow rate 
plus 5 maximum flow rate.” Bladder voiding efficiency, the 
product of bladder contractility against urethral resistance, 
was defined as the percentage of voided volume/maximum 
cystometric capacity.16,17 Side effects potentially related to 
ropivacaine and bupivacaine were also recorded.
Statistical Analysis
This randomized superiority study was designed to have 
90% power to detect a between-group difference in within-
patient PVR difference (Δ) of 180 ml during TEA post-
operatively versus before TEA using a two-sided t test at a 
significance level of 5%, assuming a SD of 210 ml.6,7 Such a 
difference is considered clinically relevant.18 This resulted in 
a sample size of 17 patients/group. Assuming a drop out of 
around 20%, 42 patients (i.e., 21 patients in the bupivacaine 
group and 21 in the ropivacaine group) were enrolled.
Statistical analyses were conducted on a modified inten-
tion-to-treat basis because patients who did not have the sec-
ond urodynamic investigation had to be excluded from the 
analysis. The data are expressed in medians with ranges for 
continuous variables or frequencies for categorical ones. For 
quantitative endpoints, the two groups were compared using 
the Wilcoxon rank-sum test, accompanied with point estimate 
and 95% CIs for Hodges–Lehmann estimator for differences 
of the two group medians for each of the pairwise compari-
sons. Within each group, the within-patient prepostoperative 
differences were analyzed using the Wilcoxon signed-rank test. 
Categorical endpoints were analyzed using the Fisher’s exact 
test. A two-sided P value of less than 0.05 was considered 
statistically significant. The statistical software used was IBM 
SPSS Statistics 24.0 (SPSS Inc., USA).
Results
Between April 2015 and May 2017, a total of 62 patients 
were assessed for eligibility, and 42 patients underwent ran-
domization. Two patients in the bupivacaine group (TEA 
with insufficient segmental blockade (n = 1) and refusal 
to undergo the second urodynamic investigation during 
TEA (n = 1) and 4 patients in the ropivacaine group (TEA 
with insufficient segmental blockade (n = 1) and refusal to 
undergo the second urodynamic investigation during TEA 
(n = 3) dropped out (fig.  2). Baseline characteristics and 
pain scores were similar between the two groups (table 1). 
The upper and lower segmental level of analgesia did not 
differ significantly between the groups. No systemic opioids 
and no sedatives were administrated postoperatively, and no 
postoperative nausea and vomiting were documented. No 
motor blockade related to TEA was present (Bromage motor 
block score of 0 in all patients). No adverse events related to 
the drugs administered occurred.
Voiding Phase
Within-patients differences in voiding phase parameters were 
all statistically significant (table 2). Median ΔPVR from base-
line to postoperatively was 300 ml (range 30 to 510; P < 0.001) 
in the bupivacaine group and 125 ml (range, −30 to 350; 
P = 0.011) in the ropivacaine group; with a significant differ-
ence between the groups (Hodges–Lehmann median differ-
ence, −175; 95% CI −295 to −40; P = 0.012; fig. 3). Median Δ 
voided volume was −320 ml (range, −800 to −50; P < 0.001) in 
the bupivacaine group and −70 ml (range, −600 to 0; P = 0.005) 
in the ropivacaine group, with a significant difference between 
the groups (Hodges–Lehmann median difference, 250; 95% 
CI, 50 to 375; P = 0.003). Median Δ maximum flow rate 
was significantly more pronounced in the bupivacaine group 
(−12 ml/s; range, −28 to 3; P < 0.001) than in the ropivacaine 
group (−4 ml/s; range, −16 to 7; P = 0.025), and this difference 
was significant between the groups (Hodges–Lehmann median 
difference, 7; 95% CI, 0 to 12; P = 0.028). Four patients 
(2 women and 2 men) in the bupivacaine group (21%) and 2 
patients (2 men) in the ropivacaine group (12%) had a maxi-
mum flow rate of 0 ml/s during TEA postoperatively and were 
totally unable to void (P = 0.664).
The bladder contractility index was significantly reduced 
in both groups: bupivacaine group (−59; range, −140 to 17; 
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Day 2 or 3 Postoperative (n=17) Day 2 or 3 Postoperative (n=19)
Fig. 2. Consolidated Standards of Reporting Trials flow diagram indicating the urodynamic protocols in the study groups. 
NRS = numerical rating scale.
Table 1. Baseline Characteristics
 
Bupivacaine
Group (n = 19)
Ropivacaine
Group (n = 17) P Value
Estimate of Group 
 Difference 95% CI
Sex (women/men) 6/13 8/9 0.342   
ASA classification (II/III) 10/9 8/9 0.739   
Age (yr) 59 (43, 77) 55 (27, 70) 0.999 −4 −14 to 3
IPSS 2 (0, 7) 3 (1, 6) 0.235 1 0 to 2
IPSS QoL (1/2/3) 10/9/0 7/7/3 0.159   
Epidural mixture rate postoperatively (ml/h) 8 (4, 12) 8 (4, 12) 0.334 −1 −2 to 1
NRS at rest 0 (0, 3) 0 (0, 3) 0.650 0 0 to 0
NRS during mobilization 2 (1, 5) 2 (1, 5) 0.524 0 −1 to 0
Segmental blockade      
  Upper thoracic dermatome 4 (3, 6) 4 (4, 6) 0.986 0 0 to 0
  Lower thoracic dermatome 12 (11, 12) 12 (10, 12) 0.899 0 0 to 0
The data are presented as count or median value (range).
ASA = American Society of Anesthesiologists; CI = confidence interval; IPSS = international prostate symptom score; QoL = quality of life; NRS = numeric 
rating scale for pain, in which 0 = no pain and 10 = worst pain imaginable.
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P < 0.001) ropivacaine group (−28; range, −114 to 26; P = 0.002), 
and this difference was significant between the groups (Hodges–
Lehmann median difference, 31; 95% CI, 4 to 59; P = 0.022). 
Bladder voiding efficiency was significantly reduced in the bupi-
vacaine group (−53%; range, −100 to 3; P < 0.001) but not in 
the ropivacaine group (−10%; range, −100 to 9; P = 0.124); this 
difference was significant between the groups (Hodges–Lehmann 
median difference 42; 95% CI, 4 to 71; P = 0.016).
Storage Phase
Between-group differences in storage phase parameters did not 
differ significantly (table 3). Within-patient median Δ bladder 
compliance was −46 ml/cmH2O (range, −473 to 45; P < 0.001) 
in the bupivacaine group. No adverse events (urinary tract 
infections, pain in the urinary tract requiring analgesic treat-
ment) related to the urodynamic investigations occurred.
Discussion
TEA with ropivacaine has a less pronounced effect on void-
ing function than with bupivacaine. Although segmen-
tal blockade from around T4 to T12 with both drugs was 
associated with a relevant impairment in voiding function, 
patients in the bupivacaine group developed clinically rel-
evant PVRs. The median ΔPVR of at least 200 ml during 
TEA in the bupivacaine group represents a clinically relevant 
impairment in voiding function, which is associated with an 
Table 2. Within-patient Absolute Values and Difference (Value during TEA – Baseline Value) and Between-group Estimate of 
Difference (Ropivacaine Group vs. Bupivacaine Group) of the Parameters of the Voiding Phase
 
Median (Range) Ropivacaine vs. Bupivacaine Group
Bupivacaine
Group (n = 19)
Ropivacaine
Group (n = 17) Estimates (95% CI) P Value*
Postvoid residual (ml)   −175 (−295 to −40) 0.012
  Baseline 10 (0 to 70) 25 (0 to 95)   
  During TEA 325 (50 to 700) 125 (0 to 350)   
  Within-patient difference 300 (30 to 510) 125 (−30 to 350)   
  P value† < 0.001 0.011   
Voided volume (ml)   250 (50 to 375) 0.003
  Baseline 520 (150 to 960) 350 (210 to 600)   
  During TEA 125 (0 to 745) 300 (0 to 535)   
  Within-patient difference −320 (−800 to -50) −70 (−600 to 0)   
  P value† < 0.001 0.005   
Maximum detrusor pressure (cmH2O)   4 (−8 to 12) 0.842
  Baseline 33 (1 to 80) 35 (10 to 75)   
  During TEA 23 (0 to 80) 29 (0 to 74)   
  Within-patient difference −7 (−35 to 50) −3 (−52 to 1)   
  P value† 0.017 0.003   
Detrusor pressure at maximum flow rate (cmH2O)   7 (−5 to 19) 0.250
  Baseline 28 (8 to 60) 34 (8 to 61)   
  During TEA 15 (0 to 62) 25 (0 to 60)   
  Within-patient difference −12 (−31 to 7) −5 (−46 to 8)   
  P value† 0.001 0.013   
Maximum flow rate (ml/s)   7 (0 to 12) 0.028
  Baseline 18 (11 to 42) 16 (9 to 20)   
  During TEA 6 (0 to 27) 11 (0 to 27)   
  Within-patient difference −12 (−28 to 3) −4 (−16 to 7)   
  P value† < 0.001 0.025   
Bladder contractility index   31 (4 to 59) 0.022
  Baseline 125 (91 to 228) 114 (87 to 132)   
  During TEA 48 (0 to 150) 80 (0 to 154)   
  Within-patient difference
P value†
−59 (−140 to 17)
 < 0.001
−28 (−114 to 26)
0.002
  
Bladder voiding efficiency (%)   42 (4 to 71) 0.016
  Baseline 97 (65 to 174) 95 (60 to100)   
  During TEA 27 (0 to 100) 85 (0 to 103)   
  Within-patient difference −53 (−100 to 3) −10 (−100 to 9)   
  P value† < 0.001 0.124   
*Within-group P value derived from the Wilcoxon signed rank test for within-patient value during TEA – baseline value difference of each endpoint. †Between-
group P value from Wilcoxon rank sum test for within-patient value during TEA – baseline value difference. Point estimates for Hodges–Lehmann median 
difference with 95% CI were constructed accordingly. Two-sided P value < 0.05 as statistically significant.
CI = confidence interval; TEA = thoracic epidural analgesia.
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increased risk of complications (urinary tract infection).19 
In addition, 21% of the patients in the bupivacaine group 
and 12% in the ropivacaine group were completely unable 
to void (i.e., urine flow rate of 0), even though we could not 
detect a statistical significance; this finding is clinically rel-
evant because these patients need catheterization.
Our results confirm our previous observation that seg-
mental blockade with epidurally administered local anes-
thetics results in detrusor underactivity and a decreased flow 
rate.8 However, the administration of ropivacaine resulted 
in less dramatic reduction of urinary flow rate, explaining 
the lower ΔPVR and higher voided volume differences com-
pared to bupivacaine. The differences in bladder contractil-
ity index reflecting the strength of detrusor contraction and 
bladder voiding efficiency were larger in the bupivacaine 
group, reflecting the greater impact on the detrusor muscle 
also significantly reduced in the bupivacaine group com-
pared to the ropivacaine group.
Bupivacaine and ropivacaine have nearly identical chemi-
cal structure; the only difference is a propyl group and a 
butyl group attached to the pipechol ring for ropivacaine 
and bupivacaine, respectively, making ropivacaine a smaller 
molecule than bupivacaine.10 The analgesic potency of ropi-
vacaine is around 60% of that of bupivacaine. For this rea-
son, to achieve an equipotent effect, bupivacaine 0.125% was 
compared with ropivacaine 0.2%, and we did find similar 
pain scores at rest and during mobilization in the two groups. 
Ropivacaine, however, produced a greater dissociation of sen-
sory to motor block than bupivacaine. This is in line with 
the fact that in terms of motor block, ropivacaine is 66% less 
potent than bupivacaine.20,21 In addition, there is a minimal 
advantage in terms of toxicity in favor of ropivacaine. The 
reduced effect of ropivacaine on detrusor contractility could 
be explained by a decreased affinity for sodium channels in 
motor neurons. Different affinities for various subtypes of 
sodium channels have been demonstrated in other studies, 
m
l
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Fig. 3. Differences in postvoid residual urine volume shown 
as median with interquartile ranges and with maximum and 
minimum values (P = 0.012).
Table 3. Within-patient Absolute Values and Difference (Value during TEA – Baseline Value) and Between-group Estimate of 
Difference (Ropivacaine Group vs. Bupivacaine Group) of the Parameters of the Storage Phase
 Median (Range) Ropivacaine vs. Bupivacaine Group
 
Bupivacaine
Group (n = 19)
Ropivacaine
Group (n = 17) Estimate (95% CI) P Value*
Bladder volume at first desire to void (ml)   13 (−61 to 55) 0.730
  Baseline 260 (30 to 470) 180 (80 to 355)   
  During TEA 220 (50 to 610) 200 (60 to 400)   
  Within-patient difference −8 (−120 to 195) 5 (−100 to 320)   
  P value† 0.825 0.649   
Bladder volume at strong desire to void (ml)   45 (−25 to 123) 0.128
  Baseline 460 (140 to 815) 305 (160 to 625)   
  During TEA 385 (100 to 700) 310 (85 to 500)   
  Within-patient difference −50 (−315 to 160) −5 (−165 to140)   
  P value† 0.021 0.415   
Maximum cystometric capacity (ml)   −28 (−100 to 70) 0.413
  Baseline 545 (200 to 970) 420 (210 to 625)   
  During TEA 460 (140 to 745) 350 (140 to 540)   
  Within-patient difference −14 (−420 to 245) −41 (−190 to 10)   
  P value† 0.287 0.003   
Compliance (ml/cmH2O)   35 (−8 to 72) 0.842
  Baseline 89 (17 to 500) 50 (19 to 100)   
  During TEA 36 (13 to 240) 35 (17 to 400)   
  Within-patient difference −46 (−473 to 45) −10 (−100 to 25)   
  P value† < 0.001 0.109   
*Between-group P value from Wilcoxon rank sum test for within-patient value during TEA – baseline value difference. Point estimates for Hodges–Lehmann 
median difference with 95% CI were constructed accordingly. Two-sided P value < 0.05 as statistically significant. †Within-group P value derived from the 
Wilcoxon signed rank test for within-patient value during TEA – baseline value difference of each endpoint. 
CI = confidence interval; TEA = thoracic epidural analgesia.
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e.g., the subtype Na(v)1.8.22 It is unclear, however, how this 
applies to ropivacaine. In addition, ropivacaine is less lipo-
philic than bupivacaine. The decreased lipophilicity reduces 
the penetration of the larger myelinated nerve fibers (Aα, Aβ, 
and Aδ fibers) by ropivacaine due to the substitution of the 
pipecoloxylidine with a three-carbon side chain instead of a 
four-carbon side chain.23,24 In a similar way, the less lipophilic 
properties of ropivacaine could result in smaller amounts of 
local anesthetic penetrating the dura mater, which would 
further explain the decreased potency and smaller degree of 
motor block.25 This remains speculative because these are in 
vitro observations and with higher concentrations than used 
in this study.26–28 The different physiochemical properties of 
the two local anesthetics may also play a role because ropiva-
caine is an almost pure L-isomer, and bupivacaine is a race-
mic mixture; the D-isomer of bupivacaine could alter receptor 
binding in larger nerve fibers.9
Another issue is the nature of the epidural space and the 
distribution of local anesthetics, demonstrated in a cadaver 
study using cryomicrotome sections. Hogan et al.29 found 
that the distribution of drugs injected in the epidural space 
follows paths between structures according to pressures by 
which they are compressed. This could explain the wide CIs 
and why some patients in both groups were able to void with 
unchanged voided volumes and PVRs while others had blad-
der retention with detrusor undercontractility.
Bupivacaine also had a greater effect on bladder compli-
ance than ropivacaine, however, without fulfilling the crite-
ria of a low compliant bladder.30 This observation is similar 
to our precedent studies involving epidurally administered 
bupivacaine 0.125% with or without additional fentanyl. 
On the other hand, maximum cystometric capacity was sig-
nificantly reduced in the ropivacaine group. This may explain 
the more effective voiding because the less-filled bladder may 
contract more effectively according to the law of Laplace.
Early catheter removal after surgery in an attempt to avoid 
or minimize the rate of urinary tract infections and urethral 
trauma has become a major focus of interest and is part of 
enhanced recovery programs.31–33 Despite the reduced effect 
of ropivacaine on bladder function, proper assessment and 
monitoring of PVRs during TEA is still recommended 
because some patients were unable to void. Because patients 
report a sensation of bladder filling even when the bladder 
is not filled, an objective quantification is mandatory even 
in case if sensory function should be considered as intact.34
We are aware of certain limitations of our study: silent 
voiding dysfunction may be unmasked during TEA or after 
surgery, and our study was not placebo-controlled; however, 
placebo TEA for postoperative analgesia would give rise to 
ethical concerns. In this study, we considered a PVR of more 
than 200 ml clinically relevant in patients with normal preop-
erative voiding function; however, this value has been chal-
lenged. Brouwer et al.35 found that using an individual residual 
volume based on maximum cystometric capacity rather than a 
fixed volume could lead to a decrease in catheterization.
In conclusion, thoracic epidurally administrated bupi-
vacaine 0.125% led to a more pronounced impairment of 
detrusor activity with a greater increase in PVRs than ropi-
vacaine 0.2%. Based on our results, ropivacaine 0.2% is the 
preferred drug to achieve early catheter removal. However, 
because detrusor contractility is also affected with ropivacaine 
0.2%, careful monitoring of PVRs remains recommended.
Acknowledgments
The authors thank the nurses of the urodynamic unit and To-
bias Metzger, M.D., Department of Urology, University Hos-
pital Bern, Bern, Switzerland, for their valued collaboration.
Research Support
Supported by the institutional research funds of the Depart-
ment of Anesthesiology and Pain Medicine and of the De-
partment of Urology, Inselspital, University Hospital Bern, 
Bern, Switzerland.
Competing Interests
The authors declare no competing interests.
Reproducible Science
Full protocol available at: patrick.wuethrich@insel.ch. Raw 
data available at: patrick.wuethrich@insel.ch.
Correspondence
Address correspondence to Dr. Wuethrich: University Hos-
pital Bern, CH-3010 Bern, Switzerland. patrick.wuethrich@
insel.ch. Information on purchasing reprints may be found 
at www.anesthesiology.org or on the masthead page at the 
beginning of this issue. ANESTHESIOLOGY’s articles are made 
freely accessible to all readers, for personal use only, 6 
months from the cover date of the issue.
References
 1. Baldini G, Bagry H, Aprikian A, Carli F: Postoperative uri-
nary retention: Anesthetic and perioperative considerations. 
ANESTHESIOLOGY 2009; 110:1139–57
 2. Givens CD, Wenzel RP: Catheter-associated urinary tract 
infections in surgical patients: A controlled study on the 
excess morbidity and costs. J Urol 1980; 124:646–8
 3. Klevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes 
RP, Pollock DA, Cardo DM: Estimating health care-associated 
infections and deaths in U.S. hospitals, 2002. Public Health 
Rep 2007; 122:160–6
 4. Foxman B: Epidemiology of urinary tract infections: 
Incidence, morbidity, and economic costs. Am J Med 2002; 
113(suppl 1A):5S–13S
 5. Rosseland LA, Stubhaug A, Breivik H, Medby PC, Larsen HH: 
[Postoperative urinary retention]. Tidsskr Nor Laegeforen 
2002; 122:902–4
 6. Wuethrich PY, Burkhard FC, Panicker JN, Kessler TM: Effects 
of thoracic epidural analgesia on lower urinary tract function 
in women. Neurourol Urodyn 2011; 30:121–5
 7. Wuethrich PY, Kessler TM, Panicker JN, Curatolo M, Burkhard 
FC: Detrusor activity is impaired during thoracic epidural anal-
gesia after open renal surgery. ANESTHESIOLOGY 2010; 112:1345–9
 8. Wuethrich PY, Metzger T, Mordasini L, Kessler TM, Curatolo 
M, Burkhard FC: Influence of epidural mixture and surgery 
Copyright © 2017, the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Anesthesiology 2017; XXX:00-00 9 Girsberger et al.
PERIOPERATIVE MEDICINE
on bladder function after open renal surgery: A randomized 
clinical trial. ANESTHESIOLOGY 2013; 118:70–7
 9. Meister GC, D’Angelo R, Owen M, Nelson KE, Gaver R: A 
comparison of epidural analgesia with 0.125% ropivacaine 
with fentanyl versus 0.125% bupivacaine with fentanyl dur-
ing labor. Anesth Analg 2000; 90:632–7
 10. Beilin Y, Halpern S: Focused review: Ropivacaine versus 
bupivacaine for epidural labor analgesia. Anesth Analg 2010; 
111:482–7
 11. Madersbacher S, Pycha A, Klingler CH, Schatzl G, Marberger 
M: The International Prostate Symptom score in both sexes: 
A urodynamics-based comparison. Neurourol Urodyn 1999; 
18:173–82
 12. Hampson SJ, Noble JG, Rickards D, Milroy EJ: Does residual 
urine predispose to urinary tract infection? Br J Urol 1992; 
70:506–8
 13. Schäfer W, Abrams P, Liao L, Mattiasson A, Pesce F, 
Spangberg A, Sterling AM, Zinner NR, van Kerrebroeck P; 
International Continence Society: Good urodynamic prac-
tices: Uroflowmetry, filling cystometry, and pressure-flow 
studies. Neurourol Urodyn 2002; 21:261–74
 14. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten 
U, van Kerrebroeck P, Victor A, Wein A; Standardisation 
Sub-committee of the International Continence Society: The 
standardisation of terminology of lower urinary tract func-
tion: Report from the Standardisation Sub-committee of the 
International Continence Society. Neurourol Urodyn 2002; 
21:167–78
 15. Curatolo M, Petersen-Felix S, Arendt-Nielsen L: Sensory 
assessment of regional analgesia in humans: A review of 
methods and applications. ANESTHESIOLOGY 2000; 93:1517–30
 16. Abrams P: Bladder outlet obstruction index, bladder contrac-
tility index and bladder voiding efficiency: Three simple indi-
ces to define bladder voiding function. BJU Int 1999; 84:14–5
 17. Osman NI, Chapple CR, Abrams P, Dmochowski R, Haab 
F, Nitti V, Koelbl H, van Kerrebroeck P, Wein AJ: Detrusor 
underactivity and the underactive bladder: a new clinical 
entity?: A review of current terminology, definitions, epide-
miology, aetiology, and diagnosis. Eur Urol 2014; 65:389–98
 18. Panicker JN, Fowler CJ: The bare essentials: uro-neurology. 
Pract Neurol 2010; 10:178–85
 19. Truzzi JC, Almeida FM, Nunes EC, Sadi MV: Residual urinary 
volume and urinary tract infection: When are they linked? J 
Urol 2008; 180:182–5
 20. Lacassie HJ, Columb MO, Lacassie HP, Lantadilla RA: The 
relative motor blocking potencies of epidural bupivacaine 
and ropivacaine in labor. Anesth Analg 2002; 95:204–8
 21. Lacassie HJ, Habib AS, Lacassie HP, Columb MO: Motor block-
ing minimum local anesthetic concentrations of bupivacaine, 
levobupivacaine, and ropivacaine in labor. Reg Anesth Pain 
Med 2007; 32:323–9
 22. Ekberg J, Jayamanne A, Vaughan CW, Aslan S, Thomas L, 
Mould J, Drinkwater R, Baker MD, Abrahamsen B, Wood 
JN, Adams DJ, Christie MJ, Lewis RJ: muO-conotoxin MrVIB 
selectively blocks Nav1.8 sensory neuron specific sodium 
channels and chronic pain behavior without motor deficits. 
Proc Natl Acad Sci U S A 2006; 103:17030–5
 23. Casati A, Putzu M: Bupivacaine, levobupivacaine and ropi-
vacaine: Are they clinically different? Best Pract Res Clin 
Anaesthesiol 2005; 19:247–68
 24. Kuthiala G, Chaudhary G: Ropivacaine: A review of its phar-
macology and clinical use. Indian J Anaesth 2011; 55:104–10
 25. Higuchi H, Adachi Y, Kazama T: Factors affecting the spread 
and duration of epidural anesthesia with ropivacaine. 
ANESTHESIOLOGY 2004; 101:451–60
 26. Bader AM, Datta S, Flanagan H, Covino BG: Comparison of 
bupivacaine- and ropivacaine-induced conduction blockade in 
the isolated rabbit vagus nerve. Anesth Analg 1989; 68:724–7
 27. Feldman HS, Covino BG: Comparative motor-blocking 
effects of bupivacaine and ropivacaine, a new amino amide 
local anesthetic, in the rat and dog. Anesth Analg 1988; 
67:1047–52
 28. Zaric D, Nydahl PA, Philipson L, Samuelsson L, Heierson 
A, Axelsson K: The effect of continuous lumbar epidural 
infusion of ropivacaine (0.1%, 0.2%, and 0.3%) and 0.25% 
bupivacaine on sensory and motor block in volunteers: A 
double-blind study. Reg Anesth 1996; 21:14–25
 29. Hogan Q: Distribution of solution in the epidural space: 
Examination by cryomicrotome section. Reg Anesth Pain 
Med 2002; 27:150–6
 30. Cho SY, Yi JS, Oh SJ: The clinical significance of poor bladder 
compliance. Neurourol Urodyn 2009; 28:1010–4
 31. Basse L, Werner M, Kehlet H: Is urinary drainage necessary 
during continuous epidural analgesia after colonic resection? 
Reg Anesth Pain Med 2000; 25:498–501
 32. Zaouter C, Kaneva P, Carli F: Less urinary tract infection 
by earlier removal of bladder catheter in surgical patients 
receiving thoracic epidural analgesia. Reg Anesth Pain Med 
2009; 34:542–8
 33. Leuck AM, Wright D, Ellingson L, Kraemer L, Kuskowski MA, 
Johnson JR: Complications of Foley catheters: Is infection the 
greatest risk? J Urol 2012; 187:1662–6
 34. De Wachter S, Van Meel TD, Wyndaele JJ: Can a faked cys-
tometry deceive patients in their perception of filling sensa-
tions?: A study on the reliability of spontaneously reported 
cystometric filling sensations in patients with non-neuro-
genic lower urinary tract dysfunction. Neurourol Urodyn 
2008; 27:395–8
 35. Brouwer TA, Rosier PF, Moons KG, Zuithoff NP, van Roon 
EN, Kalkman CJ: Postoperative bladder catheterization 
based on individual bladder capacity: A randomized trial. 
ANESTHESIOLOGY 2015; 122:46–54
Copyright © 2017, the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
